Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7410693 | 1.00 | F2 (0.37) | F2LMNAPPM1BTSHRGAA | |
| SCHEMBL7415226 | 1.00 | F2 (0.37) | F2LMNAPPM1BTSHRGAA | |
| SCHEMBL15903870 | 0.86 | TDP1 (0.39) | GAAKMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL5692181 | 0.76 | PKM (0.35) | LMNAMAPTNPC1RAB9ACYP2C9 | |
| SCHEMBL30686187 | 0.71 | LMNA (0.38) | LMNATSHRGAAKMT2AMAPT | |
| SCHEMBL10392788 | 0.66 | LMNA (0.44) | F2LMNATSHRGAAKMT2A | |
| SCHEMBL636837 | 0.63 | LMNA (0.48) | F2LMNAPPM1BTSHRGAA | |
| SCHEMBL1751897 | 0.63 | LMNA (0.48) | F2LMNAPPM1BTSHRGAA | |
| SCHEMBL637664 | 0.63 | LMNA (0.48) | F2LMNAPPM1BTSHRGAA | |
| SCHEMBL30526381 | 0.63 | F2 (0.48) | F2LMNATSHRGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452258-A | A kind of preparation method of dipeptides valine Boroproline salt | BALMXY PHARMACEUTIC CO LTD | 2019-11-15 | — | — | CN | claimed |
| CN-106699812-A | Method for preparation and purification of tenofovir prodrug | 江苏豪森药业集团有限公司 | 2017-05-24 | — | — | CN | claimed |
| US-4259383-A | PEROXY COMPOUNDS | STERLING DRUG INC. (US) | 1981-03-31 | — | — | US | claimed |
| CN-109738560-B | Method for measuring content of tartaric acid optical isomer | 宜昌人福药业有限责任公司 | 2020-11-03 | — | — | CN | disclosed |
| US-7968748-B2 | Process for resolving racemic mixtures and a diastereoisomeric complex of a resolving agent and an enantiomer of interest | ABIOGEN PHARMA S.P.A. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2009-11-26 | — | — | US | disclosed |
| EP-1986996-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | Abiogen Pharma S.p.A. (IT) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007088571-A2 | A PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | ABIOGEN PHARMA S.P.A. (IT) | 2007-08-09 | — | — | WO | disclosed |
| JP-2003335766-A | METHOD FOR PRODUCING DIBENZOYLTARTARIC ACID AND ACID ANHYDRIDE THEREOF | NIPPON LIGHT METAL CO LTD | 2003-11-28 | — | — | JP | disclosed |
| EP-0256586-B1 | PROCESS FOR THE PREPARATION OF ESTERS OF 4-(2,3-EPOXYPROPOXY)PHENYLACETIC ACID AND 4-(2-HYDROXY-3-ISOPROPYLAMINO-PROPOXY)PHENYLACETIC ACID AND/OR ATENOLOL IN STEREOSPECIFIC FORM | GIST-BROCADES N.V. (NL) | 1992-05-13 | — | — | EP | disclosed |
| EP-0256586-A1 | Process for the preparation of esters of 4-(2,3-epoxypropoxy)phenylacetic acid and 4-(2-hydroxy-3-isopropylamino-propoxy)phenylacetic acid and/or atenolol in stereospecific form | GIST-BROCADES N.V. (NL) | 1988-02-24 | — | — | EP | disclosed |
| US-4259383-A | PEROXY COMPOUNDS | STERLING DRUG INC. (US) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292129-A1 | PROCESS FOR RESOLVING RACEMIC MIXTURES AND A DIASTEREOISOMERIC COMPLEX OF A RESOLVING AGENT AND AN ENANTIOMER OF INTEREST | SRR, EPHX2, ALOX5 | F2 153/4885LMNA 715/4885PPM1B 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.